![](/img/cover-not-exists.png)
Pexelizumab may be hazardous to those with ST-segment elevation myocardial infarction undergoing primary percutaneous interventions without using glycoprotein IIb–IIIa inhibitors
Gen-Min Lin, Kai-Min Chu, Chih-Lu HanVolume:
146
Year:
2011
Language:
english
DOI:
10.1016/j.ijcard.2010.10.085
File:
PDF, 73 KB
english, 2011